A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

Inclusion Criteria:

- Are ambulatory.

- Diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined
radiographically according to the modified New York criteria.

- Participants have a history of back pain ≥3 months with age at onset <45 years.

- In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory
drugs (for duration 4 weeks) or cannot tolerate NSAIDS.

- If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization.

- Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

Exclusion Criteria:

- Have total ankylosis of the spine.

- Have received any prior, or are currently receiving, treatment with biologics, tumor
necrosis factor inhibitors or other immunomodulatory agents.

- Have recently received a live vaccine within 12 weeks or have had a vaccination with
Bacillus Calmette-Guerin (BCG) within the past year.

- Have an ongoing or serious infection within the last 12 weeks or evidence of active
tuberculosis.

- Have a compromised immune system.

- Have any other serious and/or uncontrolled diseases.

- Have either a current diagnosis or a recent history of malignant disease.

- Have had major surgery within 8 weeks of baseline, or will require surgery during the
study.

- Are pregnant or breastfeeding.